1 unchanged sentence
Rule 10b5-1 trading arrangements
−Removed: During the three months ended March 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
+Added: During the three months ended June 30, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
Reference is made to the Index to Exhibits included herein.
163 unchanged sentences
(portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-Q for the quarter ended March 31, 2023 on April 28, 2023 and incorporated herein by reference.)
+Added: 10.19.3* Letter Agreement, dated May 9, 2025, by and between Amgen Inc.
+Added: and BeiGene Switzerland GmbH, a wholly owned subsidiary of BeiGene, Ltd.
10.20 Guarantee, dated as of October 31, 2019, made by and among BeiGene, Ltd.
32 unchanged sentences
and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.) (Filed as an exhibit to Form 10-K for the year ended December 31, 2023 on February 14, 2024 and incorporated herein by reference.)
+Added: 10.22.6* Amendment No.
+Added: 9 to the Collaboration Agreement, dated May 20, 2025, by and between Amgen Inc.
+Added: and AstraZeneca Collaboration Ventures, LLC (portions of the exhibit have been omitted because they are both (i) not material and (ii) is the type of information that the Company treats as private or confidential.)
10.23 License and Collaboration Agreement, dated June 1, 2021, by and between Amgen Inc.
23 unchanged sentences
(+ = management contract or compensatory plan or arrangement)
+Added: ( 1 In May 2025, BeiGene, Ltd.
+Added: changed its name to BeOne Medicines Ltd., and BeiGene Switzerland GmbH changed its name
+Added: to BeOne Medicines I GmbH.)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: May 1, 2025 By:
+Added: August 5, 2025 By:
/ S / PETER H.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.